Functionally selective 5-HT2A agonists or ‘psychoplastogens’ like TBG designed to isolate the desired anti-inflammatory and neuro-reparative properties from the profound psychoactive effects—represent the most promising path forward for harnessing these mechanisms for MS therapy. This evidence concerns the gene HTR2A and myeloid sarcoma.